Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 19/20 | 0.65 |
| ▸ | OXTR | P30559 | 12/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024948 | 0.97 | AVPR1A (0.62) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2128605 | 0.91 | AVPR1A (0.56) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL6024950 | 0.91 | AVPR1A (0.56) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2129412 | 0.90 | AVPR1A (0.54) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL6024946 | 0.90 | AVPR1A (0.54) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18944423 | 0.86 | AVPR1A (0.52) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2128826 | 0.86 | AVPR1A (0.52) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18917267 | 0.85 | AVPR1A (0.57) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2128928 | 0.85 | AVPR1A (0.52) | AVPR1AOXTRAVPR2 | |
| SCHEMBL5567012 | 0.84 | AVPR1A (0.63) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969587-B2 | Detection of nucleic acid heteroduplex molecules by anion-exchange chromatography | ADS BIOTEC INC. | 2005-11-29 | — | — | US | claimed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7225079-B2 | System and method for automated matched ion polynucleotide chromatography | TRANSGENOMIC, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7138518-B1 | Liquid chromatographic separation of polynucleotides | TRANSGENOMIC, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7135289-B2 | Methods and compositions for mutation analysis of polynucleotides by liquid chromatography | TRANSGENOMIC, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-7125492-B2 | Additives for reversed-phase HPLC mobile phases | AGILENT TECHNOLOGIES, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1660501-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2006-05-31 | — | — | EP | disclosed |
| EP-1451350-A4 | METHODS, SYSTEMS, AND KITS FOR ANALYSIS OF POLYNUCLEOTIDES | TRANSGENOMIC INC (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| US-6210885-B1 | COVALENTLY ATTACHING CHEMICAL TAG TO POLYNUCLEOTIDE, APPLYING TO SEPARATION MEDIUM HAVING NON-POLAR SURFACE, ELUTING TAGGED POLYNUCLEOTIDE FROM SURFACE WITH MOBILE PHASE OF COUNTERION AGENT AND ORGANIC SOLVENT, AND DETECTING POLYNUCLEOTIDE | TRANSGENOMIC, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-2001019485-A1 | IMPROVED COLUMN FOR DNA SEPARATION BY MATCHED ION POLYNUCLEOTIDE CHROMATOGRAPHY | TRANSGENOMIC, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001002418-A1 | METHOD AND SYSTEM FOR RNA ANALYSIS BY MATCHED ION POLYNUCLEOTIDE CHROMATOGRAPHY | TRANSGENOMIC, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-1056528-A1 | METHOD FOR HIGH RESOLUTION LIQUID CHROMATOGRAPHIC SEPARATION OF POLYNUCLEOTIDES | TRANSGENOMIC, Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1023463-A1 | MODIFYING DOUBLE STRANDED DNA TO ENHANCE SEPARATIONS BY MATCHED ION POLYNUCLEOTIDE CHROMATOGRAPHY | TRANSGENOMIC, Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| US-6066258-A | MATCHED ION POLYNUCLEOTIDE CHROMATOGRAPHY. | TRANSGENOMIC, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6056877-A | APPLYING MIXTURE TO NONPOROUS BEADS WITH HYDROCARBON COATING; CHROMATOGRAPHY | TRANSGENOMIC, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6024878-A | CHROMATOGRAPHIC METHOD FOR SEPARATING A MIXTURE OF HETERODUPLEX AND HOMODUPLEX DNA MOLECULES UNDER CONDITIONS WHICH SELECTIVELY DENATURE A MUTATION SITE PRESENT IN THE HETERODUPLEX DNA MOLECULE | TRANSGENOMIC, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999022839-A1 | METHOD FOR HIGH RESOLUTION LIQUID CHROMATOGRAPHIC SEPARATION OF POLYNUCLEOTIDES | TRANSGENOMIC, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999019514-A1 | MODIFYING DOUBLE STRANDED DNA TO ENHANCE SEPARATIONS BY MATCHED ION POLYNUCLEOTIDE CHROMATOGRAPHY | TRANSGENOMIC, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | AVPR1A 6/4885OXTR 1/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.